APA

Petru E., Angleitner-Boubenizek L., Reinthaller A., Deibl M., Zeimet A. G., Volgger B., Stempfl A. & Marth C. (20060829). Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. : Gynecologic oncology.

Chicago

Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet A G, Volgger B, Stempfl A and Marth C. 20060829. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. : Gynecologic oncology.

Harvard

Petru E., Angleitner-Boubenizek L., Reinthaller A., Deibl M., Zeimet A. G., Volgger B., Stempfl A. and Marth C. (20060829). Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. : Gynecologic oncology.

MLA

Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet A G, Volgger B, Stempfl A and Marth C. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. : Gynecologic oncology. 20060829.